Patent US3651947A successfully refreshed from Google Patents.
US5574008A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biologically active fragments of glucagon-like insulinotropic peptide
Assignee: Eli Lilly and Co
•
Filing: 1994-08-30
•
Granted: 1996-11-12
•
Expires: 2014-08-30
Abstract
Abstract N-terminal truncated forms of glucagon like insulinotropic peptide (GLP-1) and analogs thereof are provided. The claimed polypeptides promote glucose uptake by cells but do not stimulate insulin expression or secretion. The invention also provides methods for treating diabetes and pharmaceutical formulations comprising the claimed polypeptides.
Inventors
- 👤 William T. Johnson
- 👤 Fatima E. Yakubu-Madas
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:26
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/605; A; A61; A61K; A61K38/00
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
89 words
A GLP- 1 fragment of the formula: R.sup.1 -Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-TrP-Leu-Val-X-Gly-Arg-R.sup.2 (SEQ ID NO:1) wherein R 1 is selected from the group consisting of: a) H 2 N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser (SEQ ID NO:7); and, b) H 2 N-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser (SEQ ID NO:8); X is selected from the group consisting of Lys and Arg; and wherein R 2 is selected from the group consisting of NH 2 , OH, Gly-NH 2 , and Gly-OH, with the proviso that when R 1 is b) and R 2 is Gly-NH 2 or Gly-OH, X must be Arg.
Claim 2
Dependent Claim
89 words
A GLP- 1 fragment of the formula: R.sup.1 -Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-TrP-Leu-Val-X-Gly-Arg-R.sup.2 (SEQ ID NO:1) wherein R 1 is selected from the group consisting of: a) H 2 N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser (SEQ ID NO:7); and, b) H 2 N-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser (SEQ ID NO:8); X is selected from the group consisting of Lys and Arg; and wherein R 2 is selected from the group consisting of NH 2 , OH, Gly-NH 2 , and Gly-OH, with the proviso that when R 1 is b) and R 2 is Gly-NH 2 or Gly-OH, X must be Arg.
Claim 3
Dependent Claim
19 words
The GLP-1 fragment of claim 1 that has the amino acid sequence: H 2 N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 (SEQ ID NO:9).
Claim 4
Dependent Claim
20 words
A pharmaceutical composition comprising the GLP-1 fragment of claim 2 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
Claim 5
Dependent Claim
34 words
A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of the GLP-1 fragment of claim 2, or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
12 words
The method of claim 4 wherein the mammal is a human being.
Claim 7
Dependent Claim
34 words
A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of a GLP-1 fragment of claim 1, or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
12 words
The method of claim 6 wherein the mammal is a human being.
Claim 9
Dependent Claim
19 words
The GLP-1 fragment of claim 1 that has the amino acid sequence: H 2 N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-NH 2 (SEQ ID NO:13).
Claim 10
Dependent Claim
20 words
A pharmaceutical composition comprising the GLP-1 fragment of claim 8 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
Claim 11
Dependent Claim
34 words
A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of the GLP-1 fragment of claim 8, or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
12 words
The method of claim 10 wherein the mammal is a human being.
Claim 13
Dependent Claim
18 words
The GLP-1 fragment of claim 1 that has the amino acid sequence: H 2 N-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-Gly-OH (SEQ ID NO:10).
Claim 14
Dependent Claim
20 words
A pharmaceutical composition comprising the GLP-1 fragment of claim 12 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
Claim 15
Dependent Claim
34 words
A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of the GLP-1 fragment of claim 12, or a pharmaceutically acceptable salt thereof.
Claim 16
Dependent Claim
12 words
The method of claim 14 wherein the mammal is a human being.
Claim 17
Dependent Claim
19 words
The GLP-1 fragment of claim 1 that has the amino acid sequence: H 2 N-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH 2 (SEQ ID NO:11).
Claim 18
Dependent Claim
20 words
A pharmaceutical composition comprising the GLP-1 fragment of claim 16 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
Claim 19
Dependent Claim
34 words
A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of the GLP-1 fragment of claim 16, or a pharmaceutically acceptable salt thereof.
Claim 20
Dependent Claim
12 words
The method of claim 18 wherein the mammal is a human being.
Claim 21
Dependent Claim
20 words
A pharmaceutical composition comprising a GLP-1 fragment of claim 1 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
Claim 22
Independent Claim
31 words
A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of a GLP-1 fragment having the amino acid sequence: ##STR1##
Claim 23
Independent Claim
31 words
A method of treating diabetes in a mammal comprising administering to a mammal in need of such treatment an effective amount of a GLP-1 fragment having the amino acid sequence: ##STR1##
Claim 24
Dependent Claim
12 words
The method of claim 21 wherein the mammal is a human being.
References Cited (Backward Citations)
EP0082731A1
Cited
WO1987006941A1
Cited
US5118666A
Cited
US5120712A
Cited
WO1990011296A1
Cited
WO1991011457A1
Cited
WO1993018786A1
Cited
WO1993025579A1
Cited
EP0619322A2
Cited
US5512549A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-11-12 | 2000-05-13 | 2000-11-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-11-12 | 2004-05-13 | 2004-11-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-11-12 | 2008-05-13 | 2008-11-12 | $7700.00 | Window Closed / Lapsed |